Dec 18 $220 / $260 Bull Call Spread
Buy 1x $220C · Sell 1x $260C · 32d
Updated Nov 17, 2026 7:30 PM ET · Prev Close $215.27
Options traders are heavily buying puts on MRNA, with 72% of volume in puts. This suggests bearish institutional positioning.
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 2.2% on average.
Compare deploying $21,527 for 100 MRNA shares against capped-risk 5-day option structures priced at 83.7% ATM implied volatility.
Buy 1x $220C · Sell 1x $260C · 32d
Sell 1x $190P · Buy 1x $180P · 32d
Buy 1x $230P · Sell 1x $190P · 32d
See exact institutional strike concentrations, volume-to-OI ratios, and multi-leg payoff blueprints with Tradestie Pro.
The firm sees a gap between Moderna's 87.1 billion market value and what its pipeline can justify
Moderna's MRNA phase 3 adjuvant melanoma data establishes clinical proof of concept for individual
Boost ROI through next-gen delivery platforms that differentiate biologics, extend patent life, enable precision therapies and meet demand for non-invasive, connected care.Dublin, Nov. 17, 2026 Globe Newswire -- Drug and
Regeneron Grows 36 , Gilead Spends About USD 12.7 Billion on Four Deals and Pharma Buyers Race to Refill Pipelines Precedence Research Company Intelligence on Leaders, Investments and DevelopmentsOttawa, Nov. 17, 2026 GL
Watch for breakdown below $205.74
Sessions in the past year where MRNA moved >3.0% down:
StockTwits messages express bullish sentiment towards Moderna ($MRNA) due to its potential cancer vaccine, with some traders regretting missed opportunities. The latest Yahoo Finance article discusses Moderna's stock performance and growth expectations, suggesting that the stock may be overvalued.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clin...
Receive an email alert when MRNA triggers an unusual volume breakout, options sweep, or rating shift.
Options traders are heavily buying puts on MRNA, with 72% of volume in puts. This suggests bearish institutional positioning.
Today's session carries a 70% catalyst conviction score on 0.32x relative volume (low participation). Our multi-factor model currently rates MRNA as HOLD. Review full valuation, quality, and timing signals on the MRNA Buy or Sell Decision Brief →
At $205.74, MRNA's modeled 1-to-3 session range is $199.56 – $209.85, with a key inflection level at $195.45 (support). Compare current price against multi-year cash flow projections in the MRNA Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
RSI at 44.5 reflects soft below-midline momentum. MRNA trades at $205.74 relative to its 20-day SMA ($228.10) and 50-day SMA ($204.38), reflecting a mixed moving-average structure.
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.